Wegovy seeks insurance edge in Korea's obesity drug war
Story summaryCompetition in Korea's obesity drug market is intensifying. Novo Nordisk seeks national health insurance coverage for Wegovy, aiming to regain ground against Eli Lilly's market-leading Mounjaro before Hanmi Pharmaceutical launches its newly approved homegrown rival, Eppe. Novo Nordisk Korea applied to the Health Ins…
Read at The Korea HeraldOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.